에 대한 최신 뉴스 Baxter Intl (NYSE:BAX) 주식

Baxter Intl

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Baxter International

benzinga_deal_dispatch2

Entertainment

Asset Sales

Media

AMPS

BLCO

GRAB

NSANY

PCHM

PSFE

Sony Group Corporation American Depositary Shares

SONY

TYO:4188

블록에 등장한 신규 기업들팜켐(OTC:PCHM), 약물 감지 땀 패치의 대표 기업이 전략적 대안을 모색하고 있다(즉, 인수합병 또는 매각). 이사회는 지금까지 은행가를 고용하는 것보다 독자적으로 상황을 처리할 수 있다고 자신감을 나타냈다. 관심 있는 인수자는 공식 데이터룸에 접근할 수 있다.

딜 디스패치: 팜켐이 독자 매각을 진행, TGI 프라이데이는 $1,900만 에 19개의 레스토랑 매각

Flags,Of,Puerto,Rico,And,The,Usa,Against,The,Background

Equities

Latin America

News

Markets

BPOP

EVTC

여러 회사들이 화요일 푸에르토리코의 대규모 정전으로 영향을 받을 수 있다. 무슨 일이 있었나요: 이 섬에 서비스를 제공하는 전력 회사 루마 에너지(Luma Energy)에 따르면, 현재 푸에르토리코 주민의 약 12%만 전기가 공급되고 있다고 한다.

푸에르토리코 블랙아웃: 전 섬 규모의 대규모 정전에 영향 받는 8개의 주식

Healthcare Sector Boost

Analyst Color

Health Care

Trading Ideas

General

박스터 인터내셔널(NYSE:BAX)은 허리케인 헬렌으로 인한 심각한 피해로 인해 최대 규모의 제조 시설을 폐쇄했다. 치명적인 위력으로 미국 남동부를 강타한 이 허리케인은 지역 전체에 정전과 홍수를 촉발했다.

허리케인 헬렌이 노스캐롤라이나의 핵심 제조업체 박스터 인터내셔널의 제조 시설을 마비

Baxter International Inc

BABB

Baxter Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) short percent of float has fallen 4.88% since its last report. The company recently reported that it has 17.27 million shares sold short, which is 5.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Baxter Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746712823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Baxter Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Baxter Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Baxter Intl's peer group average for short interest as a percentage of float is 4.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Baxter Intl's Recent Short Interest

Morgan Stanley analyst Patrick Wood maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Underweight and lowers the price target from $30 to $28.

Price Target

Analyst Ratings

Morgan Stanley Maintains Underweight on Baxter Intl, Lowers Price Target to $28

Wells Fargo analyst Larry Biegelsen maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Equal-Weight and lowers the price target from $36 to $33.

Wells Fargo Maintains Equal-Weight on Baxter Intl, Lowers Price Target to $33

WIIM

BAX stock has given up its prior gain. Baxter International shares were trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

On Thursday, Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported a first-quarter 2025 adjusted EPS of 62 cents, beating the management guidance of 47 to 50 cents and the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">Wall Street estimate of 48 cents</a>.
The medical device company reported sales of $2.63 billion. That&#8217;s up 5% year over year on both a reported and operational basis, beating the <a href="https://www.benzinga.com/pressreleases/25/05/b45130401/baxter-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">consensus of $2.59 billion</a>.
The management expected Q1 sales growth of 3%-4% on a reported basis and approximately 4% on an operational basis.
Companywide top-line performance on both a reported and operational basis exceeded Baxter&#8217;s previously announced guidance. The company credits its better-than-expected sales in the Medical Products &amp; Therapies and Healthcare Systems &amp; Technologies segments.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/entertainment/25/02/43566305/deal-dispatch-pharmchem-forgoes-banker-to-run-sale-tgi-fridays-sells-19-restaurants-for-3-1-million" rel="noreferrer noopener">Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million</a>
Medical Products &amp; Therapies&nbsp;sales increased 3% (+6% on constant currency) at $1.26 billion.
<ul>
<li>Growth in the quarter reflected strength in the Infusion Therapies &amp; Technologies division, driven by strong demand for IV infusion pumps and nutrition therapies, particularly in the United States; and solid performance in the Advanced Surgery division, driven by robust growth internationally.</li>
</ul>
Healthcare Systems &amp; Technologies sales for the first quarter totaled approximately $704 million. That&#8217;s an increase of 6% on both a reported and operational basis.
<ul>
<li>Growth was fueled by strong U.S. sales for Patient Support Systems products within the segment's Care and Connectivity Solutions division. Positive performance in the Front Line Care division reflected a favorable year-over-year comparison as well as further stabilization in the primary care markets in the United States.&nbsp;</li>
</ul>
Pharmaceutical&nbsp;sales reached $581 million, an increase of 1% on a reported basis and 3% on an operational basis.
<ul>
<li>Positive performance in the quarter was driven by mid-single-digit growth globally for specialty injectables, which was partially offset by a low single-digit decline in anesthesia and low single-digit growth in Drug Compounding, which reflected a difficult comparison to the prior-year period.&nbsp;</li>
</ul>
&#8220;Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey,&#8221; said Brent Shafer, chair and interim chief executive officer&#8230;While today&#8217;s global macroeconomic factors are creating a greater degree of uncertainty in the market, we remain confident in our overarching trajectory.&#8221;
Guidance: Baxter raises 2025 adjusted EPS from $2.45-$2.55 to $2.47-$2.55 versus consensus of $2.49, with sales growth of 7%-8% compared to prior guidance of 5%-6% on a reported basis and 4%-5% on an operational basis.
Baxter expects Q2 2025 adjusted EPS of 59 to 63 cents. The consensus was 61 cents, with sales growth of 4%-5% on a reported basis and 1%-2% on an operational basis.
Price Action:&nbsp;BAX stock is up 4.38% at $32.54 at the last check on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45136577/xerox-misses-q1-estimates-in-seasonally-lowest-quarter-ceo-cites-macro-and-trade-uncertainties" target="_blank" rel="noreferrer noopener">Xerox Misses Q1 Estimates In Seasonally Lowest Quarter, CEO Cites Macro And Trade Uncertainties</a></li>
</ul>
Image: Shutterstock

Earnings

Large Cap

Guidance

Movers

Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps

Baxter International shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) is looking for Q2 Adj EPS of $0.59-$0.63 vs $0.61 analyst estimate. sees sales of $3.964 billion-$4.003 billion vs $2.83 billion analyst estimate.

Baxter Intl Sees Q2 Adj EPS $0.59-$0.63 vs $0.61 Est; Expects sales growth from continuing operations of 4% to 5% on a reported basis.

Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) raises FY2025 Adj EPS guidance from $2.45-$2.55 to $2.47-$2.55 vs $2.49 analyst estimate. Raises FY2025 sales outlook from $11.17 billion-$11.27 billion to $11.38 billion-$11.49 billion vs $11.20 billion estimate.

Baxter Intl Raises FY2025 Adj EPS Guidance from $2.45-$2.55 to $2.47-$2.55 vs $2.49 Est; Sales  from continuing operations of 7% to 8% on a reported basis.

Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.48 by 29.17 percent. This is a 4.62 percent decrease over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $2.63 billion which beat the analyst consensus estimate of $2.59 billion by 1.46 percent. This is a 5.42 percent increase over sales of $2.49 billion the same period last year.

Earnings Beats

Baxter Intl Q1 Adj. EPS $0.62 Beats $0.48 Estimate, Sales $2.63B Beat $2.59B Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Baxter Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) short percent of float has risen 13.65% since its last report. The company recently reported that it has 18.16 million shares sold short, which is 5.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Baxter Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744984833_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Baxter Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Baxter Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Baxter Intl's peer group average for short interest as a percentage of float is 4.30%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Baxter Intl?

Baxter Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) short percent of float has fallen 12.66% since its last report. The company recently reported that it has 18.33 million shares sold short, which is 4.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Baxter Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743088515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Baxter Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Baxter Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Baxter Intl's peer group average for short interest as a percentage of float is 4.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Baxter Intl's Recent Short Interest

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays raised Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) price target from $39 to $41. Barclays analyst Matt Miksic maintained an Overweight rating. Baxter International shares closed at $36.57 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BAX/analyst-ratings">view this stock</a>.</li>
<li>Barclays boosted the price target for Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) from $940 to $980. Barclays analyst Karen Short maintained an Equal-Weight rating. Costco shares closed at $964.31 on Friday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised SLM Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) price target from $32 to $38. Morgan Stanley analyst Jeffery Harte maintained an Overweight rating. SLM shares closed at $29.46 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/SLM/analyst-ratings">view this stock</a>.</li>
<li>B of A Securities slashed the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $333 to $318. B of A Securities analyst Joshua Shanker maintained a Buy rating. Progressive shares closed at $279.82 on Friday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from $38 to $32. Baird analyst Andrew Wittmann maintained a Neutral rating. WillScot Holdings shares closed at $28.07 on Friday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) price target from $200 to $217. HC Wainwright &amp; Co. analyst Oren Livnat maintained a Buy rating. Jazz Pharmaceuticals shares settled at $138.81 on Friday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) price target from $13.7 to $29. Citigroup analyst Jeff Chung upgraded the stock from Neutral to Buy. XPeng shares closed at $23.60 on Friday. <a href="https://www.benzinga.com/quote/XPEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) price target from $423 to $380. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. Sherwin-Williams shares closed at $363.62 on Friday.  <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark raised the price target for DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) from $44 to $51. Benchmark analyst Mike Hickey maintained a Buy rating. DraftKings shares settled at $39.41 on Friday. <a href="https://www.benzinga.com/quote/dkng/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) price target from $165 to $185. Jefferies analyst John Colantuoni upgraded the stock from Hold to Buy. Airbnb shares closed at $134.39 on Friday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

COST

DKNG

JAZZ

XPEV

DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday

Barclays analyst Matt Miksic maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Overweight and raises the price target from $39 to $41.

Barclays Maintains Overweight on Baxter Intl, Raises Price Target to $41

During the last three months, 4 analysts shared their evaluations of Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Baxter Intl and provided 12-month price targets. The average target is $38.0, accompanied by a high estimate of $42.00 and a low estimate of $35.00. Surpassing the previous average price target of $37.50, the current average has increased by 1.33%.
<img src="https://www.benzinga.com/files/images/story/2025/1740578440_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Baxter Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Baxter Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Baxter Intl compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Baxter Intl's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Baxter Intl's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BAX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Baxter Intl analyst ratings.</a>
<h2>Unveiling the Story Behind Baxter Intl</h2>
Baxter International Inc offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
<h3>Understanding the Numbers: Baxter Intl's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Baxter Intl displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 0.99%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Baxter Intl's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -18.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Baxter Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.9%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Baxter Intl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Baxter Intl's debt-to-equity ratio stands notably higher than the industry average, reaching 1.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Baxter Intl: Insights From 4 Analyst Reviews

Goldman Sachs analyst David Roman reinstates Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Buy and announces $42 price target.

Initiation

Goldman Sachs Reinstates Buy on Baxter Intl, Announces $42 Price Target

JP Morgan analyst Robbie Marcus maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and lowers the price target from $38 to $36.

JP Morgan Maintains Neutral on Baxter Intl, Lowers Price Target to $36

On Thursday, Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>)&nbsp;reported a fourth-quarter 2024 adjusted EPS of 58 cents, beating the management guidance of 50 cents-53 cents and the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Wall Street estimate of 52 cents</a>.
The medical device company <a target="_blank" href="https://www.benzinga.com//node/43844310" rel="noreferrer noopener">reported sales of</a> $2.75 billion, up 1% year over year (+2% on a constant currency basis), beating the consensus of $2.67 billion.
The fourth quarter&#8217;s top-line performance exceeded previous guidance, driven by better-than-expected sales in the company&#8217;s Medical Products &amp; Therapies and Pharmaceuticals segments.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Medical Products &amp; Therapies&nbsp;sales were flat at $1.31 billion at reported rates and up low single digits at constant currency rates due to reduced sales of IV solutions, which, as expected, declined due to the impact of Hurricane Helene.
Infusion systems product portfolio, parenteral nutrition products, and strong demand for Advanced Surgery products drove the growth.
Pharmaceutical unit sales increased 8% to $643 million, driven by double-digit growth in specialty injectables, reflecting continued momentum from recent new product launches and ongoing strength in Drug Compounding.
Healthcare Systems &amp; Technologies&nbsp;sales declined 1% to $784 million. Sales growth in the U.S. Care and Connectivity Solutions division was fueled by strength in the Patient Support Systems business due to upgrades from existing customers and new competitive wins, offset by select product/market exits.
Guidance: Baxter expects 2025 adjusted EPS of $2.45-$2.55 versus consensus of $2.47, with sales growth of 5%-6% on a reported basis and 4%-5% on an organic basis.
Baxter expects Q1 2025 adjusted EPS of $0.47-$0.50 versus consensus of $0.52, with sales growth of 3%-4% on a reported basis and approximately 4% on an operational basis.
In the third quarter earnings release, Baxter said it anticipates a full-year 2025 adjusted operating margin of approximately 16.5% on a continuing operations basis, which reflects an anticipated 100 basis point negative impact due to stranded costs. The company expects to offset these <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">stranded costs in 2027</a>.
Price Action: BAX stock is up 8.14% at $33.33 at the last check on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43846469/walmart-q4-earnings-shine-but-soft-fy26-outlook-disappoints-street" target="_blank" rel="noreferrer noopener">Walmart Q4 Earnings Shine, But Soft FY26 Outlook Disappoints Street</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Baxter Q4 Earnings Beat Expectations, Issues Strong 2025 Outlook

Baxter International shares are trading higher after the company reported better-than-expected Q4 financial results.

Baxter Expects Q1 2025 Adjusted EPS Of $0.47-$0.50 Versus Consensus Of $0.52, With Sales Growth Of 3%-4% On Reported Basis And Approximately 4% On Operational Basis

Press Releases

Baxter Unveils Voalte Linq Device Powered by Scotty Assistant at HIMSS25 to Advance Voice-Activated Technology in Hospital Settings

Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery

Baxter to Host First-Quarter 2025 Financial Results Conference Call for Investors

Baxter to Present at Bank of America Securities 2025 Health Care Conference

Baxter Reports First-Quarter 2025 Results

Baxter Declares Quarterly Dividend

BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025

BXLT

EMBC

HSIC

PRTC

Abbott Laboratories

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Morgan Stanley

Wells Fargo

Barclays

Goldman Sachs

JP Morgan

<h2 class="wp-block-heading">블록에 등장한 신규 기업들</h2>
팜켐(OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCHM#OTC">PCHM</a>), 약물 감지 땀 패치의 대표 기업이 전략적 대안을 모색하고 있다(즉, 인수합병 또는 매각). 이사회는 지금까지 은행가를 고용하는 것보다 독자적으로 상황을 처리할 수 있다고 자신감을 나타냈다. 관심 있는 인수자는 <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">공식 데이터룸</a>에 접근할 수 있다.
이번 주 경매 블록의 다른 아이템들:
<ul>
<li>온타리오 교원연기금(Ontario Teachers&#8217; Pension Plan)이 라자(Lazard)를 고용하여 컴플라이언스 소프트웨어 회사 미트라테크(Mitratech)의 매각 프로세스를 운영하도록 했다. 로이터는 거래 규모가 약 40억 달러에 이를 것으로 추정하고 있다.</li>
<li>페이세이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>)가 2020년에 <a href="https://www.benzinga.com/news/20/12/18678982/paysafe-goes-public-again-in-spac-deal-what-investors-should-know">SPAC을 통해 상장된</a> 것을 기억하자. 현재, 블룸버그에 따르면 <a href="https://www.bloomberg.com/news/articles/2025-02-06/paysafe-is-said-to-weigh-sale-after-getting-takeover-interest?srnd=phx-deals">매각 대상</a>이 되고 있다. 억만장자 빌 폴리(Bill Foley)가 지원하는 이 회사는 인수 관심을 받고 있다.</li>
<li>스위스에 본사를 둔 뱅크 J. 사프라 사라신(Bank J. Safra Sarasin)은 덴마크의 삭소 은행에 대한 인수 제안을 검토 중이다. 이는 <a href="https://www.bloomberg.com/news/articles/2025-02-03/safra-sarasin-is-said-to-explore-deal-for-denmark-s-saxo-bank?srnd=phx-deals">블룸버그</a>에 의해 보도되었다.</li>
</ul>
<h2 class="wp-block-heading">블록에서의 업데이트</h2>
<ul>
<li>베리타스 캐피털(Veritas Capital)은 월스트리트 데이터 제공업체 던 앤 브래드스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNB#NYSE">DNB</a>)를 인수하기 위해 접촉 중이다. <a href="https://www.bloomberg.com/news/articles/2025-02-07/veritas-is-said-in-talks-to-acquire-data-firm-dun-bradstreet?srnd=phx-deals">블룸버그</a>에 따르면, 던 앤 브래드스트리트의 시장 가치는 49억 달러이다.</li>
<li>바슈 + 롬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>)은 바슈 헬스 컴퍼니스(Bausch Health Companies Inc.)와의 &#8220;완전 분리&#8221;를 고려했다. 잠재적 구매자들과의 협상 후, 그 과정은 거래로 이어지지 않았다. 이 회사는 완전한 분리를 목표로 하고 있음을 확인했다. 2024년 전체 연간 수익은 2월 19일에 발표될 예정이다.</li>
<li>KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)는 일본 기술 그룹 후지 소프트를 인수하려고 한다. 이 사모펀드는 경쟁사 베인 캐피털를 제치기 위해 제안을 약 43억 달러로 인상했다.</li>
<li>베인은 후지 소프트 거래가 성사되지 않을 경우를 대비해 다른 거래를 진행 중이다. <a href="https://www.bloomberg.com/news/articles/2025-02-06/bain-is-said-to-near-3-billion-deal-for-mitsubishi-pharma-unit?srnd=phx-deals">블룸버그에 따르면</a>, 이 회사는 미츠비시 케미컬 홀딩스(TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:4188#TYO">4188</a>)의 제약 부문을 인수하기 위해 거의 33억 달러 이상을 지불할 예정이다.</li>
</ul>
<h2 class="wp-block-heading">블록에서 나온 거래들</h2>
<ul>
<li>한편, 베인 캐피털는 밀라크론(Milacron)의 51% 지분을 <a href="https://www.plasticsnews.com/news/hillenbrand-sells-majority-stake-milacron-bain-capital-287m">인수하기로 합의</a>했다. 밀라크론은 플라스틱 가공 장비 및 서비스 제공업체이며, 힐렌브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HI#NYSE">HI</a>)는 이 지분을 2억 8천7백만 달러에 매각했다.</li>
<li>리버우드 캐피털(Riverwood Capital)은 뮌헨에 본사를 둔 소매업체 및 브랜드 가격 책정 플랫폼 퀵리자드(TASE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/qlrd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QLRD" data-google-interstitial="false">QLRD</a>)를 약 5천2백만 달러에 인수하기로 합의했다.</li>
<li>TPG는 미국의 상업용 규모의 태양광 발전소 소유업체 알투스 파워(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>)를 약 22억 달러에 인수하기로 합의했다.</li>
<li>또 다른 태양광 관련 거래: 턴/리버 캐피털(Turn/River Capital)은 텍사스 오스틴에 본사를 둔 솔라윈즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>)를 44억 달러에 인수하기로 합의했다. 이는 2월 6일 목요일 주가 종가 대비 35% 프리미엄이다.</li>
<li>몬트리올에 본사를 둔 발소프트(Valsoft)는 코아츄 매니지먼트(Coatue Management)와 바이킹 글로벌 인베스터(Viking Global Investors)의 지원을 받아 브라질의 클라우드 기반 공증인 관리 소프트웨어 제공업체 VHL 시스테마스(VHL Sistemas)를 인수했다.</li>
<li>BCI, 캐나다 자산 관리 회사가 룩셈부르크에 본사를 둔 투자사 BBGI 글로벌 인프(LSE:BBGIB)를 약 10억 파운드 (12억 4천만 달러)에 인수하기로 합의했다.</li>
<li>EP 글로벌 코머스, 억만장자 다니엘 크레틴스키(Daniel Kretinsky)가 지원하는 회사가 메트로를 20억 유로 (27억 6천만 달러)로 <a href="https://www.bloomberg.com/news/articles/2025-02-06/czech-billionaire-kretinsky-seeks-to-take-metro-private-again?srnd=phx-deals" target="_blank" rel="noopener">인수</a>했다. 이는 독일 뒤셀도르프에 본사를 두고 있다.</li>
<li>데이터브릭스, 620억 달러로 평가된 회사가 블레이드브릿지(BladeBridge)를 <a href="https://www.infoworld.com/article/3817328/databricks-acquires-bladebridge-to-aid-data-warehouse-migrations.html" target="_blank" rel="noopener">인수</a>하여 기업 데이터 웨어하우스 마이그레이션을 강화했다.</li>
<li>JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)은 독일의 세코노미 AG 인수에 대한 관심을 되살렸다고 한다. 이 중국 전자상거래 거인은 2023년에 <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43496221/jd-coms-stock-dips-as-ceconomy-deal-heats-up-in-germany-is-the-e-commerce-king-eyeing-expansion">독일 소매업체에 대한 관심을 마지막</a>으로 나타냈다.</li>
<li>닛산 자동차(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>)의 CEO 우치다 마코토(Makoto Uchida)는 혼다 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>)의 CEO 미베 토시히로(Toshihiro Mibe)에게 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%8B%9B%EC%82%B0-%EC%9E%90%EB%8F%99%EC%B0%A8-ceo-%ED%98%BC%EB%8B%A4-%EC%9E%90%EB%8F%99%EC%B0%A8%EC%97%90-%ED%95%A9%EB%B3%91-%ED%98%91%EC%83%81-%EC%A2%85%EB%A3%8C%EB%A5%BC-%ED%86%B5%EB%B3%B4/" target="_blank" rel="noopener">잠재적 합병 논의를 종료하겠다는 의사를 통보</a>했다.</li>
<li>브룩필드(Brookfield)는 휴스턴에 본사를 둔 전기 열 및 센싱 솔루션 제공업체 케멜렉스(Chemelex)를 17억 달러에 인수하는 거래를 완료했다. 골드만삭스는 엔벤트 일렉트릭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>)의 매각 측에서 자문을 맡았다.</li>
<li>코트 스퀘어 캐피털 파트너스와 윈드로즈 헬스 인베스터스(WindRose Health Investors)는 텍사스 프리스코에 본사를 둔 주입 회사 솔레오 헬스(Soleo Health)의 11억 달러 인수 거래를 완료했다.</li>
</ul>
<h2 class="wp-block-heading">파산 블록</h2>
판사 크리스토퍼 로페즈(Christopher Lopez)는 알렉스 존스(Alex Jones)의 미디어 회사 인포워스(Infowars)의 두 번째 경매 시도를 용이하게 하는 거래를 거부했다. NPR에 따르면 이 판결은 조에게 또 다른 임시 구제를 제공하지만, 샌디 훅 가족들이 거의 7년 전 부당성 손해배상으로 판결된 13억 달러를 회수하기 위한 노력을 지연시킨다.
로페즈 판사는 인포워스의 모회사인 프리 스피치 시스템(FSS)이 더 이상 파산 상태가 아니기 때문에 거래를 승인할 수 없다고 설명했다. 즉, 그의 판단에 따라 자산은 판매될 수 없으며, 오직 조의 회사 소유 지분만 경매에 부쳐질 수 있다. 그러나 판사는 또한 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars">이전 제안</a>을 차단했다. 이 제안은 풍자 웹사이트 디 어니언(The Onion)이 샌디 훅 희생자 가족들과 협력하여 인포워스에 입찰한 것이었다.
앞으로 로페즈는 모든 자산 판매는 간단한 현금 거래여야 한다고 강조했다. 이번 결정으로 손해배상 회수 및 조의 플랫폼 해체 가능성에 대한 경로는 여전히 불확실하다.
TGI 프라이데이는 11장소를 포함하여 19개의 추가 매장을 파산 보호 챕터 11 절차의 일환으로 매각했다. 캘리포니아 프리몬트에 본사를 둔 야다브 엔터프라이즈가 300만 달러의 부채로 16개 매장을 인수하고, 슈가로프 호스피텔리티, 전 TGI 프라이데이의 CEO 레이 블란셰트(Ray Blanchette) 소유의 회사가 3개 매장을 10만 달러에 인수하고 있다.
<h2 class="wp-block-heading">블록에서의 노트</h2>
규모 vs 범위: 이번 주 베인 캐피털은 미디어 부문에서의 트렌드를 지적했다.
미디어 거래가 &#8220;주로 산업 간 거래&#8221;가 되고 있다. 베인의 <a href="https://www.bain.com/insights/media-and-entertainment-m-and-a-report-2025/">분석</a>에 따르면, 딜로직(Dealogic)의 데이터를 사용하여 2024년 1~3분기 동안 모든 미디어 산업 M&amp;A의 절반 이상이 목표 또는 인수자가 자사 산업 외부에 있었던 것으로 나타났다.
여기 몇 가지 주목할 만한 사항들이 있다. 베인의 파트너인 니콜 마군, 매트 키스 및 알렉스 이건이 언급했다:
<ul>
<li>과거에는 월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)의 거래 대부분이 &#8220;규모&#8221; (즉, 2006년 Pixar 인수 및 2019년 21세기 폭스 인수)였으나, 현재는 &#8220;범위 거래&#8221;의 비중이 높아지고 있다. 예를 들어, 지난해 디즈니는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41052867/disneys-streaming-surge-epic-games-deal-among-key-growth-drivers-says-analyst">포트나이트의 제작사</a> 에픽 게임즈에 투자했다.</li>
<li>소니 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>)는 알라모 드래프트하우스(Alamo Drafthouse)라는 극장-저녁 식사 체인을 인수했다.</li>
<li>기업들은 또한 지속 가능한 IP를 위한 거래를 진행하고 있다: 소니 뮤직은 마이클 잭슨의 <a href="https://www.benzinga.com/general/entertainment/24/08/40515995/michael-jacksons-1-5b-catalog-lands-court-approval-for-sale-thriller-for-sony">음악 및 저작권 카탈로그</a>의 절반을 인수했다.</li>
<li>팝하우스 엔터테인먼트(Pophouse Entertainment)는 키스(Kiss)의 카탈로그와 <a href="https://www.benzinga.com/general/entertainment/24/04/38116031/sealed-with-a-kiss-rock-band-sells-legacy-for-300m-who-did-gene-simmons-get-into-bed-with">밴드 멤버의 초상권</a>를 인수했다.</li>
<li>사모펀드들은 품질 있는 IP를 보유한 소규모 제작 스튜디오에 투자하고 있다. 예를 들어, 레드버드(Redbird)는 All3Media를 인수하여 영상 분야에서 지속적인 우위를 확보하고자 했다.</li>
</ul>
위험이 있을까? &#8220;산업 간 미디어 M&amp;A에서 인수자는 이러한 거래가 다른 유형의 실사를 요구한다는 것을 빠르게 배운다&#8221;고 베인의 파트너들이 말한다. &#8220;첫째, 인수자는 목표 산업에 덜 익숙할 가능성이 높다. 또한, 범위 거래에 내재된 수익 시너지는 비용 시너지보다 실현하고 평가하기가 더 어렵다.&#8221;
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%B8%EC%9D%B4%EC%A7%80%EC%99%80-%EC%8B%A4%EB%B2%84%EC%8A%A4%EA%B0%80-%EB%A7%A4%EA%B0%81-%EC%A4%91-%EB%AF%B8%EC%8A%A4%ED%84%B0%EB%B9%84%EC%8A%A4/" target="_blank" rel="noopener">여기를 클릭하세요.</a>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

여러 회사들이 <a href="https://www.benzinga.com/topic/puerto-rico" target="_blank" rel="noopener" data-google-interstitial="false">화요일 푸에르토리코</a>의 대규모 정전으로 영향을 받을 수 있다.
무슨 일이 있었나요: 이 섬에 서비스를 제공하는 전력 회사 루마 에너지(Luma Energy)에 <a href="https://miluma.lumapr.com/outages/serviceStatus" target="_blank" rel="noopener">따르면</a>, 현재 푸에르토리코 주민의 약 12%만 전기가 공급되고 있다고 한다.
X에 게시된 글에서 루마 에너지는 정전이 화요일 오전 5시에 시작되었으며 &#8220;지하선의 고장&#8221;으로 인한 것이라고 <a href="https://x.com/lumaenergypr/status/1874081905856885124" target="_blank" rel="noopener">밝혔다</a>. 이 회사는 전력 복구 예상 시간을 24~48시간으로 제시했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Declaraciones (8:30 a.m.): LUMA activa operaciones de emergencia para restaurar la energía después de un apagón en todo el sistema   LUMA ha activado su Centro de Operaciones de Emergencia y actualmente está trabajando con Genera y demás colaboradores de generación para reiniciar…
&mdash; LUMA Puerto Rico (@lumaenergypr) <a href="https://twitter.com/lumaenergypr/status/1874081905856885124?ref_src=twsrc%5Etfw">December 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
푸에르토리코는 미국 영토로서 허리케인 마리아가 섬의 전력망을 약화시킨 이후 최근 몇 년 동안 전력 정전이 <a href="https://www.benzinga.com/general/movers-shakers/23/01/30481980/when-a-storm-leaves-you-without-power-for-days-what-do-you-do-yousolar-is-developing-solut">더 빈번</a>해졌다. 이 영토는 2023년에 에너지 생산을 논란 속에 민영화하여 전력 운영을 Genera PR에 맡겼다.
푸에르토리코 주지사 페드로 피에를루이지는 <a href="https://x.com/GovPierluisi/status/1874058818612527451">X에 게시한 글</a>에서 회사들의 정전 처리에 불만을 표명했다.
&#8220;우리는 루마와 Genera에게 답변과 해결책을 요구하고 있으며, 그들은 고장 구역 외부의 발전 유닛 재가동을 신속히 진행하고, 전 서비스 복구 조치에 대해 주민들에게 적절히 알려야 한다.&#8221;
영향을 받는 회사들: 루마 에너지는 미국 인프라 회사 콴타 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)와 캐나다 회사 ATCO 간의 합작 투자이다. Genera는 뉴 포트리스 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>)의 자회사이다.
여러 다른 상장 회사들도 푸에르토리코에서 운영되고 있다.
금융 서비스 회사인 파퓰러(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>), OFG 뱅코프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) 및 퍼스트 뱅코프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>)가 이 섬에 서비스를 제공한다. 금융 기술 회사인 에버텍(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>)는 산후안에 본사를 두고 있다.
의료 공급 회사인 박스터 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>)는 <a href="https://www.baxter.com/perspectives/community-engagement/global-response-hurricane-maria">푸에르토리코에서</a> MINI-BAG 및 MINI-BAG Plus 용기 시스템을 제조한다. 제조 대기업 하니웰 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)도 이 섬에서 운영되고 있다.
화요일은 새해 전날이기 때문에 회사들은 휴일로 인해 운영이 줄어들 수 있어 정전의 영향을 덜 받을 수 있다. 그럼에도 불구하고 반복적인 정전은 푸에르토리코 경제에 해로운 영향을 미칠 수 있다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%AF%B8%EA%B5%AD-%EB%A8%B8%EB%8B%88-%EB%A7%88%EC%BC%93-%ED%8E%80%EB%93%9C%EA%B0%80-6-75%EC%A1%B0%EB%A1%9C-%EC%82%AC%EC%83%81-%EC%B5%9C%EA%B3%A0%EC%B9%98-%EA%B8%B0%EB%A1%9D-%EC%9D%B4-%EC%9C%A0/" target="_blank" rel="noopener">미국 머니 마켓 펀드가 6.75조 달러로 사상 최대치를 기록했습니다: 이 유동 현금 잔고가 잠재적 구매력을 나타냅니까?</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

박스터 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>)은 허리케인 헬렌으로 인한 심각한 피해로 인해 최대 규모의 제조 시설을 폐쇄했다. 치명적인 위력으로 미국 남동부를 강타한 이 허리케인은 지역 전체에 정전과 홍수를 촉발했다.
노스캐롤라이나 주 매리언에 위치한 박스터의 노스 코브(North Cove) 공장은 미국 최대의 정맥주입(IV) 및 복막투석(PD) 솔루션 생산업체이다. 이 회사는 이번 혼란이 재무 성과에 부정적인 영향을 미칠 가능성이 높다고 밝혔다.
월요일, 박스터의 주가는 한때 4.1% 급락했으나, 나중에 2.42% 하락한 $37.97에 마감되었다. 이후 시간외 거래에서 이 주식은 1.74% 추가 하락했다.
모건 스탠리의 주식 분석가인 패트릭 우드(Patrick Wood)는 월요일에 허리케인 관련 중단에 대한 메모를 작성하며 폭풍으로 인한 잠재적 재정적 피해를 설명했다. 우드는 2017년 허리케인이 박스터의 푸에르토리코 생산능력에 영향을 미친 사례를 허리케인 헬렌의 선례로 언급했다.
&#8220;감지 점검을 하자면, 박스터의 4분기에 $140백만 달러의 영향을 가정할 경우(3분기는 사실상 종료된 상태), 이는 미국 만성 요법 및 주입 요법 사업 전체에 대해 약 4일간의 가동 중단을 의미한다&#8221;고 우드가 메모에 썼다. &#8220;실제로는 이것이 PD 및 IV 솔루션이 생산되는 유일한 시설이 아닐 가능성이 높으며 박스터는 아마도 생산 능력을 이동할 수 있을 것이다.&#8221;
허리케인 헬렌은 카테고리 4의 폭풍으로 목요일에 플로리다를 강타하여 시속 140마일의 바람을 동반했으며 북쪽으로 이동했다. 이 폭풍은 심각한 홍수를 일으켰고, 제방이 무너져 물이 박스터의 시설로 유입되었다. 홍수로 인해 재고와 원자재가 손상되었다고 이 회사 대변인이 전했다.
웰스 파고(Wells Fargo)의 분석가들은 ICU 메디컬(ICU Medical), 프레지니우스 카비(Fresenius Kabi) 및 비브라운(B Braun SE)와 같은 다른 회사들이 박스터의 공급 손실을 보상할 수 있을 수 있다고 지적했지만 공장 폐쇄가 미국의 의료 절차에 영향을 미칠지는 불분명하다.
박스터는 노스 코브 공장을 조속히 가동 재개하기 위해 지역 당국과 긴밀히 협력하고 있다. 다행히도 이 시설의 2,500명 직원은 모두 다치지 않았다. 그러나 이 회사는 통신 장애로 인해 직원 안전을 여전히 확인하고 있다.
사진: Unsplash
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>텐센트 뮤직 엔터테인먼트 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>)이 <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">2분기 매출</a> 부진을 보고한 후 주가는 18.18% 하락했다. 몇몇 분석가들은 주식의 <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">목표 주가</a>를 낮췄다.</li>
<li>모빌아이 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>)의 주식은 지난주 5.92% 하락했다. RBC 캐피털은 이 주식의 목표 주가를 <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">34달러에서 24달러로</a> 낮췄다.</li>
<li>리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식은 최신 공급망 혼란의 일환으로 아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)을 위해 제작하던 전기 상용 밴의 부품이 부족하다는 이유로 생산을 중단한 것으로 알려진 후 5.37% 하락했다.</li>
<li>치폴레 멕시칸 그릴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)의 주식은 회사의 회장이자 CEO인 브라이언 니콜이 <a href="https://www.benzinga.com//node/40376234" target="_blank" rel="noreferrer noopener">퇴임한다고 발표한 후</a> 4.87% 하락했다. 여러 애널리스트들이 이 주식의 평가와 <a href="https://www.benzinga.com//node/40367589" target="_blank" rel="noreferrer noopener">목표 주가를 각각 낮추었다</a>.</li>
<li>리니지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>)의 주식은 지난주 4.08%를 잃었다.</li>
<li>시리우스 XM 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)의 주식은 버크셔 해서웨이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)가 이 회사의 지분을 늘린다는 보도로 주 초에 잠시 올랐음에도 불구하고 지난주 3.85% 하락했다.</li>
<li>허시(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)의 주식은 골드만삭스가 <a href="https://www.benzinga.com//node/40321537" target="_blank" rel="noreferrer noopener">이 주식에 대해 ‘매도&#8217; 평가와</a> 1주당 185달러의 목표 주가를 제시한 이후 3.23% 하락했다.</li>
<li>백스터 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>)의 주식은 이 회사가 밴티브 키드니 케어(Vantive Kidney Care) 사업을 칼라일 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>)에 38억 달러에 매각할 <a href="https://www.benzinga.com//node/40342215">확정계약을 발표한 이후</a> 2.80% 떨어졌다.</li>
<li>브로드리지 파이낸셜 솔루션즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>)의 주식은 2.76% 하락했다.</li>
<li>유나이티드 테라퓨틱스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>)의 주식은 2.38% 하락했다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%97%94%eb%b9%84%eb%94%94%ec%95%84-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac/" target="_blank" rel="noopener">엔비디아, 스타벅스 및 델은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 11일-8월 17일)</a></li>
</ul>
사진 제공: 리비안
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

LINE

MBLY

리비안과 치폴레는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 11일-8월 17일)

Comments

Baxter Intl

뉴스

에 대한 최신 뉴스 Baxter Intl (NYSE:BAX) 주식

토요일, 2월 08, 2025

수요일, 1월 01, 2025

월요일, 9월 30, 2024

일요일, 8월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌